The EstroGenomic® Profile uses genomic testing to identify susceptibility to diseases and conditions such as breast cancer, osteoporosis, and heart disease. This profile evaluates genetic variations, called single nucleotide polymorphisms (SNPs) in genes that modulate estrogen metabolism, coagulation, cardiovascular function, bone health, and inflammation.
The EstroGenomic® Profile evaluations include:
- GST (M1 and P1)
- COMT (catechol-O-methyl transferase)
Estrogen metabolism SNPs focus on the Phase 1 enzymes involved in the formation of anti- or procarcinogenic metabolites such as 2-hydroxyestrone and 4-hydroxyestrone, respectively, as well as the Phase 2 enzymes responsible for the subsequent metabolism of these compounds. Levels of the various estrogen metabolites modulate risk of both breast cancer and osteoporosis.
- GP3a (Glycoprotein 3)
- Factor 2 (Prothrombin)
- PAI-1 (Plasminogen activator inhibitor-1)
- Factor 5 (Leiden)
These genetic variants focus on estrogens interaction with some of the key constituents of the clot formation and fibrinolysis process, such as clotting factors and inhibitors of fibrinolysis. The SNPs can over-activate blood clotting processes, increasing the risk of sudden cardiac events such as thrombosis, heart attacks, and strokes, especially among women take supplemental estrogens and oral contraceptives.
- Apo E (apoliprotein E)
These genes affect how the body processes cholesterol, responds to inflammation, and metabolizes B vitamins. The presence of these SNPs can increase risk of cardiovascular disease, hyperlipidemia, and blood vessel damage.
Osteoporosis SNPs relate to estrogens influence on inflammation, bone resorption, vitamin D function and bone collagen formation.